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Abstract
Objectives: Caregivers of patients with late-stage idiopathic Parkinson disease (IPD) and late-stage progressive supranuclear
palsy (PSP) often suffer from severe psychological strain themselves. This study investigates the influence of the different kind of
symptoms in IPD and PSP on the psychological burden of the caregivers. Methods: Twenty patients with late-stage IPD and 20
patients with late-stage PSP and their caregivers were investigated. To measure the degree of motor, cognitive, and affective
impairment of the patients, the instruments Subscale III of the Unified Rating Scale for Parkinsonism (UPDRS-III), a shortened 24-item
version of the Mini-Mental State Examination, and the Geriatric Depression Scale (GDS-30) were used. Psychological burden of the
caregivers was determined by using the Beck Depression Inventory (BDI-II) and the Zarit Caregiver Burden Inventory (ZBI).
Results: Patients with IPD suffered from a higher level of depression (GDS-30: 15.9 vs 10.2, P ¼ .020), whereas patients with PSP
showed greater motor impairment (UPDRS-III: 38.3 vs 29.9, P ¼ .002). Caregivers of both groups reported high psychological
burden (ZBI: 36.5 in IPD vs 42.8 in PSP) and symptoms of a depression (BDI-II: 12.5 in IPD vs 15.1 in PSP). No significant influence of
motor impairment, cognitive dysfunction, and depressive symptoms of the patient on the burden of the caregiver could be found.
Conclusions: Psychological strain and depression among caregivers seem to become even more relevant in the late stages of IPD
and PSP. Further studies will be necessary to investigate the specific determining factors in late-stage parkinsonian syndromes.
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Introduction
Idiopathic Parkinson disease (IPD) represents the most fre-
quent parkinsonian syndrome and the second most frequent
neurodegenerative disease in general after Alzheimer disease.
Due to the expected change in the future age structure of the
population, a further increase in the number of affected people
is predicted by experts.1 Idiopathic Parkinson disease is a pro-
gressive neurodegenerative disease belonging to the group of
a-synucleinopathies. Whereas many of its core symptoms can
be influenced by pharmacological treatment, several nonmotor
(eg, dementia, depression, psychosis) and motor problems (eg,
postural instability, dysphagia) can occur with further progres-
sion of the disease and increasing duration of drug treatment and
then show a negative impact on patient’s and caregiver’s burden
as a consequence.2 It is clinically very important to distinguish
the so-called atypical parkinsonian syndromes progressive
supranuclear palsy (PSP), multiple system atrophy (MSA), and
corticobasal degeneration (CBD) with their much worse
prognosis and much lower response to dopaminergic medication
than in IPD. Therefore, palliative care and the alleviation of
symptoms get even more important in these diseases.3-5
Progressive supranuclear palsy belongs to the group of
tauopathies and represents one of the more common variants
of atypical parkinsonian syndromes. Progressive supranuclear
palsy is a rapidly progressing disease, where patients gradu-
ally lose their ability to walk and stand even early in the
course of the disease. With further progress, characteristic
bulbar symptoms like dysphagia and a frontosubcortical
dementia occur frequently.6-8
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Until now, there is only little data about the circumstances of
life of patients with late-stage parkinsonian syndromes—in
particular of patients with the atypical variants. The caregivers
of patients with IPD are known to suffer from multiple stress
factors which are comparable with the ones that can be found in
Alzheimer disease.9,10 An increasing need of assistance (with
dressing, personal hygiene, eating, mobility, application of
medication, etc) or general dependence of the patient on the
caregiver, growing financial costs, and a lack of support can
easily lead to physical and emotional exhaustion of the care-
giver—subsumed under the term burden—in the progressive
course of the disease.10,11 From studies on patients with IPD in
earlier stages, it is known so far that the extent of motor and
neuropsychiatric symptoms seems to have an important influ-
ence on the caregiver’s burden, which can reciprocally have an
effect on the patient’s quality of life and the course of the
disease.12,13 A similar situation could be assumed for the dis-
abling PSP, but only very little is known about the true burden
of the caregivers of patients with PSP.14
The aim of this cross-sectional observational study was to
compare the psychological strain of caregivers of late-stage
patients with IPD and PSP and to scrutinize the influence of
the different load of symptoms, as well as the severity of the
disease, on the burden of the caregiver.
Methods
Study Design
Forty patients diagnosed by a movement disorder specialist
(S. Lorenzl, Agatharied; J. Schwarz, Haag) with IPD (n ¼ 20)
or PSP (n¼ 20) according to international diagnostic criteria and
currently showinga severityof symptoms according toHoehnand
Yahr staging 4 and Schwab and England Activities of Daily
LivingScale50—representing a late stage of the disease—were
included into the study together with their caregivers. As care-
givers, we accepted either partners or other family members who
had to be involved closely in the all-day care for the patient.
Patientswith all other kindsofparkinsonian syndromes (eg,MSA,
CBD, or drug-induced) as well as earlier stages of IPD and PSP
were excluded fromour study. Sample sizewas defined primarily
following previous studies and on the basis of the estimated num-
ber of patients with PSP available in Southern Germany.
All participants were recruited by contacting self-help
groups (German Parkinson Association, German PSP Associ-
ation), nursing homes, and neurological hospitals with special
departments for movement disorders (LMUMunich University
Hospital, Agatharied Hospital, Haag Hospital).
First a questionnaire containing the Beck Depression Inven-
tory (BDI-II) was sent to the participants and should be com-
pleted by the caregiver on its own. Afterward the participants
were visited within 1 week by our research team (physician,
social education worker) to conduct the other assessment
instruments and to collect the patients’ and caregivers’ socio-
demographic basic data (eg, patient age, disease duration) dur-
ing an interview. All included patients and caregivers finally
participated in the study.
The study had been approved by the local ethics committee
of the Ludwig-Maximilians-University of Munich (reference
number: 193-14). Written informed consent was obtained from
all participants of the study, and none of the participants
received any payment or other rewards for taking part.
Instruments
Data referring to the patient. Besides the Hoehn and Yahr and
the Schwab and England Activities of Daily Living Scale,
which were used to determine the inclusion criteria, the sever-
ity of the illness was assessed by the Unified Rating Scale for
Parkinsonism (UPDRS) and the level of motor impairment by
the UPDRS-III Subscale. Higher UPDRS scores correspond to
a higher severity of symptoms. To evaluate an existing cog-
nitive impairment or dementia, the popular screening tool
Mini-Mental State Examination (MMSE) was used. Scores
from 0 to 30 points can be achieved, in which lower scores
indicate a larger extent of the symptoms. Because of the influ-
ence of severe motor dysfunction (as occurring in late-stage
parkinsonian syndromes) on the results of the MMSE recog-
nized in previous studies,15 we decided to ignore the last 6
items of the test (tasks of writing and drawing), which are
strongly connected with the motor performance of the patient,
and rather use a shortened 24-item version of the MMSE in
order to assess only cognitive dysfunction as far as possible.
The limits of the MMSE were adjusted to the 24-item version,
as shown in Table 1.
To evaluate the existence of symptoms of depression in the
patient, the 30-item version of the Geriatric Depression Scale
(GDS-30) was used. Scores from 0 to 30 points can be
achieved, in which higher scores indicate a larger extent of the
symptoms. Usually, scores from 10 to 19 points are regarded as
an indication of mild to moderate and scores from 20 to 30
points as an indication of severe depressive symptoms. In the
sense of a categorical evaluation (yes/no), we also assessed
anamnestically the existence of any symptoms of psychosis
(delusions, hallucinations) at the time of the interview.
Data referring to the caregiver. General psychological strain of
the caregivers because of the patient’s present situation with
the disease was determined by the Zarit Caregiver Burden
Inventory (ZBI). It comprises 22 items, which are rated from
0 to 4 points. Higher scores indicate greater burden.
For the assessment of symptoms of depression in the care-
givers, the revised version of the BDI-II was used. Scores from
0 to 63 points can be achieved, in which higher scores indicate
Table 1. Limits of MMSE-24.
Cognitive impairment 24-Item Version 30-Item Version
Mild dementia 16-21 20-26
Moderate dementia 8-15 10-19
Severe dementia 7 9
Abbreviation: MMSE, Mini-Mental State Examination.
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a larger extent of the symptoms. Usually, scores from 9 to 13
points are regarded as minimal, from 14 to 19 points as mild,
from 20 to 28 points as moderate, and from 29 to 63 points as
severe depressive symptoms.
Data Analysis
Descriptive statistics were used for sociodemographic and clin-
ical variables. The Kolmogorov-Smirnov test was applied to
check for normality of distribution of the data, in order to
choose parametric or nonparametric tests for further statistical
analyses. Presumed differences in demographic and clinical
variables between the groups IPD and PSP were compared using
w2 test in respect of qualitative variables and 2-tailed t test or
rather Mann-Whitney U test for quantitative variables. To ana-
lyze the relationship between ZBI and BDI-II results, Spearman
rank correlation analysis was done. For statistical evaluation of a
predictability of ZBI and BDI-II results (dependent variables) by
the influence of GDS-30, MMSE-24, UPDRS-III results and the
diagnosis of IPD or PSP itself (independent variables), a multi-
ple linear regression analysis was done additionally. Statistical
analyses were performed using IBM SPSS Statistics version 23
(IBM Corp., Released 2015, Armonk, NY). A level of signifi-
cance of a ¼ .05 was accepted for all comparisons.
Results
There were no statistically significant differences in our
sample concerning gender of the patients (w2 ¼ 0.100, df ¼
1, P ¼ .752) and gender of the caregivers (w2 ¼ 0.960, df ¼ 1,
P = .327), which shows the achievement of homogeneity of
these characteristics between both groups.
As expected, patients with PSP showed a shorter mean dura-
tion of the disease until reaching the late stage compared with
patients with IPD. This difference was statistically significant
(Mann-WhitneyU test: Z¼4.141, P¼ .000) and was accom-
panied by a significantly higher age of the patients in the group
of IPD (t ¼ 2.772, df ¼ 38, P ¼ .009). Caregivers in both
groups did not show a significant difference with regard to age
(t ¼ 0.958, df ¼ 38, P ¼ .344).
Symptoms of psychosis seemed to occur more frequently in
IPDwith a borderline significance (w2¼ 3.584, df¼ 1,P = .058).
One patient with PSP and 1 patient with IPD were not able to
communicate at all because of bad condition and therefore could
not complete the tasks GDS-30 and MMSE-24. Three patients
with PSP were only able to communicate by shaking their head
and therefore could not complete the taskMMSE-24 but could do
the GDS-30. One patient with IPDwas not able to understand the
questions of GDS-30 due to severe dementia.
As shown in Table 2, further differences between the 2
groups IPD and PSP were seen in the level of symptoms of
depression, which ranges from moderate severity in IPD to
only very mild in PSP on average. This difference was statis-
tically significant (Mann-WhitneyU test: Z¼ 2.315, P¼ .020).
There were no significant differences with regard to the means
of MMSE-24 (Mann-Whitney U test: Z¼0.551, P¼ .589) to
measure the cognitive impairment between the both groups of
patients with IPD and PSP. Both showed a mean cognitive
dysfunction in the range of a mild dementia. Detailed results
are shown in Table 3. The means of UPDRS-III to measure the
motor impairment of the patient differed significantly from IPD
to PSP (t ¼ 3.371, df ¼ 38, P ¼ .002).
Caregivers of patients with IPD and PSP reported high to
very high mean burden in the ZBI. In BDI-II, their mean scores
indicate minimal depression in the group IPD and mild in the
group PSP. The differences between both groups were not
statistically significant (ZBI: t ¼ 1.582, df ¼ 30, P ¼ .124;
BDI-II: Mann-Whitney U test: Z ¼ 0.706, P ¼ .495).
In the whole sample of our study, scores of ZBI as an indi-
cator of general psychological strain of the caregivers and scores
of BDI-II as an indicator of symptoms of depression did not
show a significant correlation but a trend (rs ¼ .280, P = .081).
Table 2. Sociodemographic and Clinical Variables of Patients and
Caregivers in Both Groups of Diagnosis IPD and PSP.
Variables IPD PSP
Patients n (%) n (%)
Participants 20 (50.0) 20 (50.0)
Men 11 (55.0) 10 (50.0)
Women 9 (45.0) 10 (50.0)
Patients with psychosis 7 (35.0) 2 (10.0)
Mean (SD) Mean (SD)
Patient age, years 76.2 (6.4) 70.8 (6.0)
Disease duration, years 15.3 (7.6) 6.3 (3.0)
Hoehn and Yahr 4.3 (0.5) 4.9 (0.4)
Schwab and England ADL 23.5 (13.1) 14.0 (9.9)
UPDRS I-IV 66.5 (17.1) 78.7 (13.4)
UPDRS III 29.9 (9.1) 38.3 (6.5)
MMSE-24 (N ¼ 35; 21 path) 18.9 (6.2) 18.3 (7.1)
GDS-30 (N ¼ 37; 10 path) 15.9 (7.2) 10.2 (3.5)
Caregivers n (%) n (%)
Participants 20 (50.0) 20 (50.0)
Men 6 (30.0) 9 (45.0
Women 14 (70.0) 11 (55.0)
Mean (SD) Mean (SD)
Caregiver age, years 67.1 (10.5) 70.0 (8.6)
ZBI 36.5 (15.3) 42.8 (8.7)
BDI-II [ 9 path] 12.5 (5.5) 15.1 (8.9)
Abbreviations: BDI, Beck Depression Inventory; GDS, Geriatric Depression
Scale; IPD, idiopathic Parkinson disease; PSP, progressive supranuclear palsy;
SD, standard deviation; UPDRS, Unified Rating Scale for Parkinsonism; ZBI,
Zarit Caregiver Burden Inventory.
Table 3. Distribution of MMSE-24 Results in Both Groups.
IPD (N ¼ 19) PSP (N ¼ 16)
No dementia 9 8
Mild dementia 5 5
Moderate dementia 4 1
Severe dementia 1 2
Abbreviations: IPD, idiopathic Parkinson disease; MMSE, Mini-Mental State
Examination; PSP, progressive supranuclear palsy.
Schmotz et al 269
Multiple linear regression analysis revealed that ZBI
scores of the caregivers were not determined by the severity
of symptoms of the patient with regard to motor impairment
(UPDRS-III: standardized b ¼ .136, P ¼ .540), cognitive
impairment (MMSE-24: standardized b ¼ .046, P ¼
.807), and depressive symptoms (GDS-30: standardized b ¼
.207, P ¼ .286) in our entire sample, whereas the diagnosis of
the patient itself showed a statistical trend (standardized b ¼
.374, P ¼ .095) to be an independent contributing factor. Age
(standardized b ¼ .170, P ¼ .347) and gender (standardized
b ¼ .047, P ¼ .794) of the caregivers were instead no sig-
nificant factor. However, there was no statistically significant
influence of patient’s UPDRS-III, MMSE-24, and GDS-30 on
caregiver’s ZBI scores (corrected R2 ¼ .065, P ¼ .208).
Within the groups IPD and PSP, it was also not possible to
predict ZBI scores of the caregivers by the motor, cognitive,
or affective severity of symptoms (Table 4).
Furthermore, multiple linear regression analysis showed
that BDI-II scores of the caregivers were also not determined
by the severity of symptoms of the patient with regard to motor
impairment (UPDRS-III: standardized b ¼ .219, P ¼ .341),
cognitive impairment (MMSE-24: standardized b ¼ .073,
P = .705), and depressive symptoms (GDS-30: standardized
b ¼ .197, P ¼ .325) in our entire sample. The diagnosis of the
patient itself could also not be identified as a contributing
factor (standardized b ¼ .236, P ¼ .302), as well as age (stan-
dardized b ¼ .110, P ¼ .547) and gender (standardized b ¼
.045, P ¼ .802) of the caregivers. However, there was no
statistically significant influence of patient’s UPDRS-III,
MMSE-24, and GDS-30 on caregiver’s BDI-II scores (cor-
rected R2 ¼ .001, P ¼ .426). Within the groups IPD and PSP,
it was not possible to predict BDI-II scores of the caregivers by
the motor, cognitive, or affective severity of symptoms,
although scores seem closer associated in IPD than in PSP
(Table 5) and showed a borderline significance (P ¼ .051) for
depression in caregivers (BDI-II) and patients (GDS-30) with
IPD.
Discussion
The present study demonstrates that late-stage IPD and late-
stage PSP usually mean a considerable high psychological bur-
den for the caregivers. In our sample, it was about 1.5 (IPD) to
2 (PSP) times higher than in studies concerning parkinsonian
syndromes in earlier stages12,16,17 and seem comparable with
the results of caregivers of patients with Alzheimer disease.18
Caregivers of PSP patients seemed a little more burdened,
which could be connected with the rapid progression of the
disease and a lack of sufficient options of treatment currently
available. Unfortunately, there were not any results available
from previous studies about the care of patients with PSP,
which emphasizes the necessity of further investigation about
the late stages of atypical parkinsonian syndromes.
The extent of reported symptoms of depression (BDI-II) was
not correlated statistically significantly with the reported sub-
jective burden in ZBI in our sample but showed a possible
connection. Other studies about the burden of caregivers of
patients with Alzheimer disease even indicate an independence
of reported burden and depression in the caregivers.19 This
discrepancy may be explained by the influence of individual
vulnerability and personality-dependent factors in the patho-
genesis of depression20 and in addition can often be attributed
to an altered view of reality due to intrapsychological resis-
tance of the caregivers confronted with the devastating condi-
tion of their beloved one. Altogether, the BDI-II showed that
caregivers of both groups of diseases reach scores that indicate
the prevalence of a minimal (IPD) to mild (PSP) depression,
which is more or less in the range of studies concerning
parkinsonian syndromes in earlier stages16,21 and shows the
persisting need for professional psychological support.
When comparing the symptoms of the diseases IPD and PSP
at a similar stage, it gets obvious in our study that patients with
PSP suffered from more severe motor impairment, patients of
both groups showed mild cognitive dysfunction, whereas
patients with IPD seemed to become depressed to a marked
extent more easily.
A systematic review showed that in general symptoms of a
depression can be found in about 35% of all patients with IPD
and about 17% fulfill the criteria of a major depressive disor-
der.22 There are only few studies about depression in patients
with PSP, mostly carried out in early stages of the disease,
which vary considerably in the numbers of prevalence (18%-
60%) and the severity of symptoms.21,23-25 The noticed lower
extent of depression in patients with PSP in our study could be
associated with an assumed different pattern of affected brain
areas and circuits in the late stage of PSP where orbitofrontal
Table 4. Regression Analysis for ZBI Scores of Caregivers Within
Both Groups.
IPD Standardized b P PSP Standardized b P
UPDRS-III .173 .554 UPDRS-III .235 .480
MMSE-24 .209 .467 MMSE-24 .047 .885
GDS-30 .188 .476 GDS-30 .395 .214
Corrected R2 ¼ .060, P ¼ .581 Corrected R2 ¼ .070, P ¼ .585
Abbreviations: GDS, Geriatric Depression Scale; IPD, idiopathic Parkinson
disease; MMSE, Mini-Mental State Examination; PSP, progressive supranuclear
palsy; UPDRS, Unified Rating Scale for Parkinsonism; ZBI, Zarit Caregiver
Burden Inventory.
Table 5. Regression Analysis for BDI-II Scores of Caregivers Within
Both Groups.
IPD Standardized b P PSP Standardized b P
UPDRS-III .334 .212 UPDRS-III .282 .420
MMSE-24 .332 .206 MMSE-24 .096 .778
GDS-30 .489 .051 GDS-30 .116 .721
Corrected R2 ¼ .148, P ¼ .162 Corrected R2 ¼ .179, P ¼ .866
Abbreviations: BDI, Beck Depression Inventory; GDS, Geriatric Depression
Scale; IPD, idiopathic Parkinson disease; MMSE, Mini-Mental State Examination;
UPDRS, Unified Rating Scale for Parkinsonism; PSP, progressive supranuclear
palsy.
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and medial frontal circuits are dysfunctional in contrast to IPD
where the mesocortical monoaminergic nuclei are involved.26
Studies revealed that about 30% of patients with IPD suf-
fer from dementia and the probability to develop dementia
within 10 years after the onset of the disease is about 75%.27
Studies on dementia in patients with PSP detected inconsis-
tent results maybe because of different durations of the dis-
ease between the samples.24,28 In our study, patients with IPD
and PSP showed a mild cognitive impairment probably
according to cholinergic dysfunction and loss of white matter
found in studies.29,30
Besides, patients with PSP showed significantly higher
motor impairment than patients with IPD according to the
UPDRS-III results. This may be put down to the fact that the
caregivers of patients with IPD tried to “present” the patient
in a state as good as possible (on-state of the disease) when
we visited them, while the caregivers of patients with PSP
had no opportunity to influence the state by medication.
When taking the on–off state into consideration, our
UPDRS-III results seem comparable with other studies.31
The prevalence of symptoms of psychosis in our study
matches results of previous studies in patients with IPD.32 It
could be possible that the longer course of the disease IPD,
accompanied by a longer treatment with dopaminergic drugs,
lead to a higher occurrence of symptoms of psychosis in the
late stage of this disease.
In contrast to our results, numerous other studies suggest a
connection between motor and neuropsychiatric symptoms of
the patients and the burden of the caregivers12,33,34 but were
done mostly on patients with IPD only. Seeing the (mostly
severe) motor and neuropsychiatric symptoms of late-stage
patients, having no clear influence on the burden or the occur-
rence of symptoms of a depression in the caregivers, leads us to
the assumption that there are further crucial factors (eg, psy-
chosocial support, financial circumstances, psychological cop-
ing with the situation) which need to be investigated in further
studies. Furthermore, the borderline significant correlation
between depression in patients with IPD and their caregivers,
which could not be found within the group of PSP, clearly
demonstrates that the different courses of the diseases seem
to encourage different ways of intrapsychological processing.
The reduced statistical power due to a small sample size,
which is an indirect consequence from the low prevalence of
patients with PSP (5 to 10:100 000), can be considered as the
major limitation of this study, which other investigations
about PSP also faced before.6-8 The only way to reach higher
statistical power in spite of this rare occurrence of the disease
would be the conduction of a multinational study in order to
scrutinize the controversial results currently published but
exceeded our possibilities.
Further limitations could be seen in the discretionary powers
our investigators basically had when applying our instruments
and the inclusion criteria. We tried to minimize them by having
done all the data assessment by the same investigators to get
consistent results. Another limitation might be that caregivers
theoretically could have ignored our instructions on fulfilling
the questionnaire on their own and instead discussed the
answers with the patient or other relatives at first, which could
have slightly influenced their finally given statements then.
Since the questionnaire did contain instruments affecting the
caregiver’s very personal feelings of depression and burden, we
consider this bias by other persons as very unlikely.
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